[1] Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA,1943,121(17):1332-1334. [2] Morgan HV,Williamson DA. Jaundice following administration of human blood products. Br Med J,1943,1(4302):750-753. [3] Tobler LH,Busch MP. History of post transfusion hepatitis. Clin Chem,1997,43(8Pt2):1487-1493. [4] 杨绍基,任红. 传染病学.7版,北京:人民卫生出版社,2007:325. [5] Dienstag JL,Purcell HR,Alter HJ,et al. Non-A,non-B post-transfusion hepatitis. Lancet,1977,1(8011):560-562. [6] Choo QL,Kuo G,Weiner AJ,et al. Isolation of a cDNA clone derived from a blood-borne non-A,non-B viral hepatitis genome.Science,1989,244(4902):359-362. [7] Perz JF,Armstrong GL,Farrington LA,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol,2006,45(4):529-538. [8] Makroo RN,Walia RS,Chowdhry M,et al. Seroprevalence of anti-HCV antibodies among blood donors of north India. Indian J Med Res,2013,138:125-128. [9] Nagalo BM,Bisseye C,Sanou M,et al. Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso,West Africa. Trop Med Int Health,2012,17(2):247-253. [10] Sharma RR,Cheema R,Vajpayee M,et al. Prevalence of markers of transfusion transmissible diseases in voluntary and replacement blood donors. Natl Med J India,2004,17(1):19-21. [11] Thakral B,Marwaha N,Chawla YK,et al. Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. Indian J Med Res,2006,124(4):431-438. [12] Kato N. Genome of human hepatitis C virus (HCV):gene organization,sequence diversity,and variation. Microb Comp Genomics,2000,5(3):129-151. [13] 杨芳,邢文革. 丙型肝炎病毒的检测策略及其应用. 中华肝脏病杂志,2008,16(12):952-954. [14] Kuo G,Choo QL,Alter HJ,el a1. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science,1989,244(4902):362-364. [15] Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus.Hepatology,1992,15(2):350-353. [16] Couroucé AM,Pillonel J. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion.N Engl J Med,1996,335(21):1609-1610. [17] 尹秀华. 丙型肝炎检测方法的研究进展.医学理论与实践,2013,26(2):171-173. [18] Grant PR, Sims CM,Tedder RS. Quantification of HCV RNA levels and detection of core antigen in donations before seroconversion.Transfusion,2002,42(8):1032-1036. [19] Couroucé AM,Le Marrec N,Bouchardeau F,et al. Efficacy of HCV core antigen detection during the pre-seroconversion period. Transfusion,2000,40(10):1198-1202. [20] 张效本,阮秀花,田葱. 142例慢性丙型肝炎患者血清HCV-cag和HCV RNA检测结果分析.实用肝脏病杂志,2013,16(4):358-359. [21] Gu S,Liu J,Zhang H,et al. Core antigen tests for hepatitis C virus:a meta-analysis. Mol Biol Rep,2012,39(8):8197-8208. [22] 黄锦江,杨静,刘小琦. HCV核心抗原检测技术筛查丙型肝炎的应用评价. 医学信息,2011,24(1):256. [23] Laperehe S,LeMarree N,Girauh A,et al. Simultaneous detection of hepatitis C virus(HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol,2005,43(8):3877-3883. [24] Laperehe S,Elghouzzi MH,Morel DP,et a1. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing.Transfusion,2005,45(12):1965-1972. [25] 冷婵,邱艳,修冰水,等. 第4代Murex HCV Ag/Ab联合检测试剂在血液筛查中的应用价值. 北京医学,2012,34(04):329-332. [26] 蒋树海,杨发青,Lee T,等. 运用免疫胶体金技术快速检测丙型肝炎病毒抗体. 解放军预防医学杂志,2009,27(1):30-32. [27] 谢志贤,郭健.双向侧流胶体金法检测丙型肝炎抗体的临床评价. 中华检验医学杂志,2007,30(5):538-540. [28] Laperche S. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent.Transfusion,2013,53(4):816-826. [29] 闫忠,高卫新. 金标法抗HCV假阴性与假阳性的检测结果研究. 中国中医药资讯,2011,3(1):19. [30] 王迅. 核酸检测技术(NAT)及其在血液筛检中的应用. 中国输血杂志,2004,17(6):465-468. [31] 施欣,孙莉,高波,等. 从新版血站技术操作规程看我国血站管理的发展. 中国输血杂志,2012,25(5):508-512. [32] Roth WK,Seifried E. The German experience with NAT. Transfus Med,2002,12(4):255-258. [33] Assal A,Barlet V,Deschaseaux M,et al. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems:Procleix Tigris and cobas’s 201. Transfusion,2009,49(2):289-300. [34] Busch MP,Glynn SA,Stramer SL,et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion,2005,45(2):254-264. [35] Zou S,Dorsey KA,Notari EP,et al. Prevalence,incidence,and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.Transfusion,2010,50(7):1495-1504. [36] Schmidt M,Seifried E. Current concepts in serological testing -TTID. ISBT Sci Ser,2011,6(1):61-66. [37] 秦伟斐,李小红,田耘博,等. TMA技术检测HCV-RNA和ELISA法检测抗-HCV的比较.国际检验医学杂志,2013,34(11):1426-1428. |